Compare Stocks: ARTL, DARE, KPRX, and MBRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTL Artelo Biosciences	$0.66 -7.0%	$0.94	$0.52 ▼ $28.14	$3.27M	-0.07	508,567 shs	832,187 shs
DARE Dare Bioscience	$0.74 -1.6%	$1.52	$0.73 ▼ $3.78	$11.48M	1.08	1.10 million shs	427,911 shs
KPRX Kiora Pharmaceuticals	$2.66 +2.7%	$2.57	$1.76 ▼ $2.95	$11.46M	-0.38	17,598 shs	8,680 shs
MBRX Moleculin Biotech	$0.69 +14.8%	$1.66	$0.16 ▼ $15.75	$11.69M	1.83	2.44 million shs	1.48 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTL Artelo Biosciences	-6.98%	-7.22%	-24.89%	-52.79%	-97.55%
DARE Dare Bioscience	-1.59%	-8.71%	-37.66%	-66.87%	-63.43%
KPRX Kiora Pharmaceuticals	+2.70%	+1.53%	+3.50%	-0.75%	-6.99%
MBRX Moleculin Biotech	+14.78%	+16.61%	-68.55%	-75.32%	-95.46%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTL Artelo Biosciences	$0.66 -7.0%	$0.94	$0.52 ▼ $28.14	$3.27M	-0.07	508,567 shs	832,187 shs
DARE Dare Bioscience	$0.74 -1.6%	$1.52	$0.73 ▼ $3.78	$11.48M	1.08	1.10 million shs	427,911 shs
KPRX Kiora Pharmaceuticals	$2.66 +2.7%	$2.57	$1.76 ▼ $2.95	$11.46M	-0.38	17,598 shs	8,680 shs
MBRX Moleculin Biotech	$0.69 +14.8%	$1.66	$0.16 ▼ $15.75	$11.69M	1.83	2.44 million shs	1.48 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTL Artelo Biosciences	-6.98%	-7.22%	-24.89%	-52.79%	-97.55%
DARE Dare Bioscience	-1.59%	-8.71%	-37.66%	-66.87%	-63.43%
KPRX Kiora Pharmaceuticals	+2.70%	+1.53%	+3.50%	-0.75%	-6.99%
MBRX Moleculin Biotech	+14.78%	+16.61%	-68.55%	-75.32%	-95.46%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTL Artelo Biosciences	1.67	Reduce	N/A	N/A
DARE Dare Bioscience	2.50	Moderate Buy	$10.00	1,253.73% Upside
KPRX Kiora Pharmaceuticals	2.00	Hold	$10.00	275.94% Upside
MBRX Moleculin Biotech	2.33	Hold	$22.00	3,094.42% Upside

Current Analyst Ratings Breakdown

Latest ARTL, DARE, KPRX, and MBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/25/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	DARE Dare Bioscience	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	DARE Dare Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	DARE Dare Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	MBRX Moleculin Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/26/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	ARTL Artelo Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/11/2026	KPRX Kiora Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	$1.09 per share	N/A
DARE Dare Bioscience	$1.03M	10.97	N/A	N/A	($0.04) per share	-18.47
KPRX Kiora Pharmaceuticals	N/A	N/A	N/A	N/A	$3.81 per share	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$0.59 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTL Artelo Biosciences	-$12.88M	-$16.80	N/A	N/A	N/A	N/A	-518.27%	-194.29%	N/A
DARE Dare Bioscience	-$13.40M	-$0.70	N/A	N/A	N/A	-803.80%	-748.30%	-38.75%	11/12/2026 (Estimated)
KPRX Kiora Pharmaceuticals	-$10.84M	-$2.51	N/A	N/A	N/A	N/A	-63.38%	-44.33%	11/6/2026 (Estimated)
MBRX Moleculin Biotech	-$33.56M	-$7.13	N/A	N/A	N/A	N/A	-143.51%	-24.53%	11/12/2026 (Estimated)

Latest ARTL, DARE, KPRX, and MBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	DARE Dare Bioscience	-$0.2967	-$0.20	+$0.0967	-$0.20	$0.00 million	$0.19 million
8/13/2026	Q2 2026	MBRX Moleculin Biotech	-$1.55	-$1.40	+$0.15	-$1.40	N/A	N/A
8/12/2026	Q2 2026	ARTL Artelo Biosciences	-$0.72	-$0.89	-$0.17	-$0.89	N/A	N/A
8/7/2026	Q2 2026	KPRX Kiora Pharmaceuticals	-$0.47	-$0.34	+$0.13	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	N/A
DARE Dare Bioscience	N/A	N/A	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTL Artelo Biosciences	N/A	3.00	3.00
DARE Dare Bioscience	N/A	0.99	0.99
KPRX Kiora Pharmaceuticals	N/A	8.97	8.97
MBRX Moleculin Biotech	N/A	0.94	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTL Artelo Biosciences	0.87%
DARE Dare Bioscience	6.70%
KPRX Kiora Pharmaceuticals	76.97%
MBRX Moleculin Biotech	15.52%

Insider Ownership

Company	Insider Ownership
ARTL Artelo Biosciences	3.20%
DARE Dare Bioscience	4.10%
KPRX Kiora Pharmaceuticals	0.52%
MBRX Moleculin Biotech	1.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTL Artelo Biosciences	5	4.60 million	4.45 million	Not Optionable
DARE Dare Bioscience	30	15.29 million	14.66 million	Not Optionable
KPRX Kiora Pharmaceuticals	10	4.42 million	4.40 million	Not Optionable
MBRX Moleculin Biotech	20	19.48 million	19.26 million	Not Optionable

ARTL, DARE, KPRX, and MBRX Headlines

Recent News About These Companies

Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference

August 27 at 9:01 AM | globenewswire.com

Signal Proxy Intelligence Recommends AGAINST Moleculin Biotech, Inc. Executive Compensation Ahead of Oct. 9, 2026 Annual Meeting (NASDAQ:MBRX)

August 26 at 12:49 AM | usatoday.com

Moleculin Biotech (MBRX) Upgraded to Buy: Here's Why

August 24, 2026 | zacks.com

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

August 14, 2026 | globenewswire.com

Moleculin Biotech, Inc.: Moleculin Announces Pricing of $9.3 Million Public Offering

July 31, 2026 | finanznachrichten.de

Moleculin Biotech stock is sinking Friday: What's going on?

July 31, 2026 | msn.com

Moleculin Biotech Prices $9.3 Million Best-Efforts Public Offering with Warrants

July 31, 2026 | quiverquant.comQ

Moleculin Announces Pricing of $9.3 Million Public Offering

July 31, 2026 | globenewswire.com

Moleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

July 31, 2026 | finance.yahoo.com

Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

July 31, 2026 | globenewswire.com

Moleculin Biotech Files Registration Statement for Public Offering; Shares Fall

July 29, 2026 | finance.yahoo.com

Moleculin Biotech CEO Discusses Preliminary MIRACLE Trial Results for Annamycin in Virtual Investor Segment

July 6, 2026 | quiverquant.comQ

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment

July 6, 2026 | globenewswire.com

MBRX stock drops 25% as Moleculin Biotech's interim cancer trial data falls short of significance

July 1, 2026 | msn.com

Why is Moleculin Stock Falling Today?

June 30, 2026 | benzinga.com

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

June 30, 2026 | globenewswire.com

Moleculin Biotech Insider Trading Activity | NASDAQ:MBRX | Benzinga

June 25, 2026 | benzinga.com

Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML

June 5, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/06/05/3307353/0/en/independent-market-research-finds-strong-physician-intent-to-prescribe-moleculin-s-annamycin-in-relapsed-refractory-aml.html$

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment

June 4, 2026 | globenewswire.com

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

May 29, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARTL, DARE, KPRX, and MBRX Company Descriptions

Artelo Biosciences NASDAQ:ARTL

$0.66 -0.05 (-6.98%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$0.62 -0.04 (-6.35%)

As of 04:20 AM Eastern

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Dare Bioscience NASDAQ:DARE

$0.74 -0.01 (-1.59%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$0.73 -0.01 (-1.72%)

As of 04:33 AM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Kiora Pharmaceuticals NASDAQ:KPRX

$2.66 +0.07 (+2.70%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$2.68 +0.02 (+0.94%)

As of 08/27/2026 04:10 PM Eastern

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Moleculin Biotech NASDAQ:MBRX

$0.69 +0.09 (+14.78%)

Closing price 08/27/2026 04:00 PM Eastern

Extended Trading

$0.73 +0.04 (+5.42%)

As of 04:41 AM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARTL, DARE, KPRX, and MBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARTL, DARE, KPRX, and MBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARTL, DARE, KPRX, and MBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARTL, DARE, KPRX, and MBRX Company Descriptions

Artelo Biosciences NASDAQ:ARTL

Dare Bioscience NASDAQ:DARE

Kiora Pharmaceuticals NASDAQ:KPRX

Moleculin Biotech NASDAQ:MBRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARTL, DARE, KPRX, and MBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARTL, DARE, KPRX, and MBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARTL, DARE, KPRX, and MBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARTL, DARE, KPRX, and MBRX Company Descriptions

Artelo Biosciences NASDAQ:ARTL

Dare Bioscience NASDAQ:DARE

Kiora Pharmaceuticals NASDAQ:KPRX

Moleculin Biotech NASDAQ:MBRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools